IP Library › Granted Patent US 7,217,547
Granted Patent B2
US 7,217,547 · App. 09/965,807 · Granted May 15, 2007

Aspartoacylase gene, protein, and methods of screening for mutations associated with Canavan disease

Assignee: Miami Children's Hospital
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,217,547
App. No.
09/965,807
Granted
May 15, 2007
Kind
B2
Abstract

Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli . A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.

Claims (6)

1. An isolated human aspartoacylase polypeptide having either an altered ability to hydrolyze N-acetyl-aspartic acid to aspartate and acetate, as compared with a wild-type human aspartoacylase, or being incapable of hydrolyzing N-acetyl-aspartic acid to aspartate and acetate, and comprising the amino acid sequence SEQ ID NO: 2 or wild-type human aspartoacylase, except that said sequence has one or more of the following amino acid substitutions:

E285>A,

Y231>X, and/or

A305>E,

whereby E is glutamate, A is alanine, Y is tyrosine, and X is any naturally-occurring amino acid.

2. A human aspartoacylase of claim 1 , wherein the glutamic acid at amino acid position 285 is substituted by alanine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2014
From: MATALON, REUBEN; KAUL, RAJINDER; GAO, GUANG PING; BALAMURUGAN, KUPPAREDDI; MICHALS-MATALON, KIMBERLEE
To: MIAMI CHILDREN'S HOSPITAL RESEARCH INSTITUTE, INC.
Reel/Frame 032631/0738 →
Continuity (2)
Continuation 0812802000 · Sep 29, 1993
Related Publication 20030017473A1 · Jan 23, 2003